{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:19:33Z","timestamp":1766575173475,"version":"3.48.0"},"reference-count":19,"publisher":"Consilium Medicum","issue":"11","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To evaluate the efficacy and safety of levilimab (LVL) in patients with rheumatoid arthritis (RA) in real clinical practice.\r\nMaterials and methods. A retrospective observational study of 144 patients with RA and the need to adjust previously prescribed therapy against the background of an exacerbation of the disease, which took place at the Republican Clinical Hospital in Kazan. All patients included in the study were prescribed LVL (Ilsira). The activity of RA was assessed using Disease Activity Score 28 \u2013 DAS28-ESR\/CRP indices. The assessment was performed before initiation of LVL therapy and at the end of follow-up.\r\nResults. The analysis included 144 patients with RA (112 \u2013 women, 32 \u2013 men, average age \u2013 55.1\u00b112.3 years). The patients were divided into 3 groups, depending on the duration of follow-up. The first group (up to 4 weeks) \u2013 33 (22.9%) patients, the second group (4\u20138 weeks) \u2013 75 (52.1%), the third group (more than 8 weeks) \u2013 36 (25%). The duration of follow-up described in the study did not exceed 12 weeks. The assessment was performed before initiation of LVL therapy and at the end of follow-up. In each of the groups, at the time of completion of the observation, there was a decrease in RA activity according to the DAS28-ESR\/CRP indices by 6.1% (p=0.000162), 11.1% (p=0.00001) and 27% (p=0.0001) respectively, according to acute phase indicators \u2013 ESR by 39.6% (p=0.0001), 55.4% (p=0.0001) and 44.6% (p=0.000028) respectively, CRP decreased by 65.2% (p=0.000196), 71.5% (p=0.0001) and 58.6% (p=0.000707) respectively. At the end of the follow-up, the number of patients with high RA activity decreased by 65.8% (p=0.000022). Against the background of LVL therapy, the proportion of patients taking CS\u22657.5 mg\/day decreased by 31.4% (p=0.006). LVL's safety profile was assessed as favorable. The registered AE related to deviations in the reference values of laboratory parameters and corresponded to 1 or 2 degrees of severity according to CTCAE version 5.0. No serious AE were reported.\r\nConclusion. Levilimab has demonstrated high efficacy and a favorable safety profile for RA therapy.<\/jats:p>","DOI":"10.26442\/00403660.2025.11.203445","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:29:26Z","timestamp":1766212166000},"page":"927-932","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the efficacy and safety of levilimab in the treatment of patients with rheumatoid arthritis in real practice"],"prefix":"10.26442","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4654-4153","authenticated-orcid":false,"given":"Elvina R.","family":"Myasoutova","sequence":"additional","affiliation":[{"name":"Republican Clinical Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-652X","authenticated-orcid":false,"given":"Alina R.","family":"Iuskaeva","sequence":"additional","affiliation":[{"name":"Kazan State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1511-3686","authenticated-orcid":false,"given":"Liana S.","family":"Kostakova","sequence":"additional","affiliation":[{"name":"Republican Clinical Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6274-4636","authenticated-orcid":false,"given":"Elena V.","family":"Sukhorukova","sequence":"additional","affiliation":[{"name":"Republican Clinical Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-3238","authenticated-orcid":false,"given":"Rifkat Z.","family":"Abdrakipov","sequence":"additional","affiliation":[{"name":"Republican Clinical Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-2725","authenticated-orcid":false,"given":"Diana I.","family":"Abdulganieva","sequence":"additional","affiliation":[{"name":"Republican Clinical Hospital"},{"name":"Kazan State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7115-1513","authenticated-orcid":false,"given":"Nikita M.","family":"Taratorkin","sequence":"additional","affiliation":[{"name":"JSC \u201cBIOCAD\u201d"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"unstructured":"\u0420\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u044b\u0439 \u0430\u0440\u0442\u0440\u0438\u0442. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438. \u041c. 2021 [Revmatoidnyi artrit. Klinicheskie rekomendatsii Minzdrava Rossii. Moscow. 2021 (in Russian)].","key":"ref1"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.14412\/1995-4484-2017-590-599"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1136\/bmj-2022-070856"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1016\/j.jbspin.2018.03.018"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1007\/s40259-023-00634-1"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.2147\/DDDT.S100302"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1136\/annrheumdis-2020-217344"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.14412\/1996-7012-2024-3-32-43"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.26442\/00403660.2024.07.202907"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.14412\/1996-7012-2021-4-13-23"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1136\/ard-2022-223356"},{"doi-asserted-by":"publisher","key":"ref12","DOI":"10.1002\/acr.24596"},{"doi-asserted-by":"publisher","key":"ref13","DOI":"10.1002\/14651858.CD000011"},{"doi-asserted-by":"publisher","key":"ref14","DOI":"10.26442\/00403660.2020.05.000630"},{"doi-asserted-by":"publisher","key":"ref15","DOI":"10.1007\/s10067-022-06307-8"},{"doi-asserted-by":"publisher","key":"ref16","DOI":"10.1111\/eci.13363"},{"doi-asserted-by":"publisher","key":"ref17","DOI":"10.3389\/fmed.2021.708168"},{"doi-asserted-by":"publisher","key":"ref18","DOI":"10.1007\/s10354-010-0795-0"},{"doi-asserted-by":"publisher","key":"ref19","DOI":"10.1093\/rheumatology\/keaa529"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/690026\/215150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/690026\/215150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:15:16Z","timestamp":1766574916000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/690026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,12,20]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2025.11.203445","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2025,12,20]]}}}